10543-12-1

Basic information

• Product Name: 4-Acetoxy-3-methoxybenzoic acid
• Synonyms: 4-(acetyloxy)-3-methoxy-benzoicaci;Benzoic acid, 4-(acetyloxy)-3-methoxy-;RARECHEM AL BE 0061;O-ACETYLVANILLIC ACID;3-METHOXY-4-ACETOXYBENZOIC ACID;4-ACETOXYBENZOIC ACID, METHYL ETHER;4-ACETOXY-3-METHOXYBENZOIC ACID;4-ACETYLVANILLIC ACID
• CAS NO: 10543-12-1
• Molecular Formula: C₁₀H₁₀O₅
• Molecular Weight: 210.18
• EINECS: 234-122-2
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 10543-12-1.mol

Chemical Properties

• Melting Point: 149 °C
• Boiling Point: 327.95 °C at 760 mmHg
• Flash Point: 128.065 °C
• Appearance: /
• Density: 1.285 g/cm³
• Vapor Pressure: 7.91E-05mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.93±0.10(Predicted)
• CAS DataBase Reference: 4-Acetoxy-3-methoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Acetoxy-3-methoxybenzoic acid(10543-12-1)
• EPA Substance Registry System: 4-Acetoxy-3-methoxybenzoic acid(10543-12-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 10543-12-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Acetoxy-3-methoxybenzoic acid is used as an active pharmaceutical ingredient for its anti-inflammatory and analgesic properties, contributing to the treatment of various conditions such as pain and inflammation.
Used in Cosmetic Industry:
In the cosmetic industry, 4-Acetoxy-3-methoxybenzoic acid is used as a key ingredient in various formulations, leveraging its anti-inflammatory and analgesic properties to provide soothing and healing effects on the skin.
Used in Medical Research:
4-Acetoxy-3-methoxybenzoic acid is studied for its potential use in combating various medical conditions, including cancer and cardiovascular diseases, due to its bioactive properties and therapeutic potential.
Overall, 4-Acetoxy-3-methoxybenzoic acid is a versatile compound with applications in medicine, cosmetics, and ongoing research for novel therapeutic uses.

InChI:InChI=1/C10H10O5/c1-6(11)15-8-4-3-7(10(12)13)5-9(8)14-2/h3-5H,1-2H3,(H,12,13)

Upstream product

• 79-21-0 peracetic acid 
• 881-68-5 vanillin acetate 
• 104-15-4 toluene-4-sulfonic acid 
• 64-19-7 acetic acid 
• 60-29-7 diethyl ether 
• 5912-87-8 (E)-1-(4-acetoxy-3-methoxyphenyl)-1-propene 
• 7722-84-1 dihydrogen peroxide 
• 5447-38-1 2-(4-acetoxy-3-methoxyphenyl)acetic acid 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 108-24-7 acetic anhydride 
• 1135-24-6 3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 121-33-5 vanillin 
• 97-53-0 4-allylguaiacol 
• 93-07-2 Veratric acid 

Downstream Products

• 56681-66-4 3-methoxy-4-acetoxybenzoyl chloride 
• 99185-39-4 2-Nitro-3-methoxy-4-acetoxy-benzoesaeure 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 64-19-7 acetic acid 
• 122892-46-0 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-4-hydroxy-3-methoxy-benzamide 
• 109368-39-0 6-iodo-O¹-vanilloyl-6-deoxy-β-D-glucopyranose 
• 114510-22-4 O⁶-(toluene-4-sulfonyl)-O¹-vanilloyl-β-D-glucopyranose 
• 115893-25-9 O¹-(4-acetoxy-3-methoxy-benzoyl)-O²,O³,O⁴-triacetyl-6-iodo-6-deoxy-β-D-glucopyranose 
• 117756-35-1 O¹-(4-Acetoxy-3-methoxy-benzoyl)-O²,O³,O⁴-triacetyl-O⁶-trans-cinnamoyl-β-D-glucopyranose 
• 1041740-13-9 3,6-furan-7-(4''-hydroxy-3''-methoxyphenyl)-1-phenylheptane 

Relevant articles and documents

ACYLRESORCINOLS FROM SEED KERNELS OF MYRISTICA DACTYLOIDES

A new polyketide 1-(2,6-dihydroxyphenyl)-9-(4-hydroxy-3-methoxyphenyl)nonan-1-one and five other polyketides 1-(2,6-dihydroxyphenyl)tetradecan-1-one and malabaricones A-D have been isolated from Myristica dactyloides seeds. 13C NMR of the first and the second mentioned compounds are also reported for the first time.Key Word Index - Myristica dactyloides; Myristicaceae; seeds; polyketides; 13C NMR.

Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors

Four series of ferulic acid derivatives were designed, synthesized, and evaluated for their neuraminidase (NA) inhibitory activities against influenza virus H1N1 in vitro. The pharmacological results showed that the majority of the target compounds exhibited moderate influenza NA inhibitory activity, which was also better than that of ferulic acid. The two most potent compounds were 1m and 4a with IC50 values of 12.77 ± 0.47 and 12.96 ± 1.34 μg/ml, respectively. On the basis of the biological results, a preliminary structure–activity relationship (SAR) was derived and discussed. Besides, molecular docking was performed to study the possible interactions of compounds 1p, 2d, 3b, and 4a with the active site of NA. It was found that the 4-OH-3-OMe group and the amide group (CON) of ferulic acid amide derivatives were two key pharmacophores for NA inhibitory activity. It is meaningful to further modify the natural product ferulic acid to improve its influenza NA inhibitory activity.

Aromatic thermotropic polyesters based on 2,5-furandicarboxylic acid and vanillic acid

This paper addresses a route to synthesize bio-based polymers with an aromatic backbone having a liquid crystalline (LC) phase in the molten state. The LC phase is employed to achieve uniaxial orientation during processing required in e.g. fiber spinning. For this purpose 2,5-furandicarboxylic acid (2,5-FDCA) and O-acetylvanillic acid (AVA), obtained from natural resources, are used as monomers. Similar to the 2,6-hydroxynapthoic acid used to perturb the crystalline packing of poly(oxybenzoate) in the Vectran series, these bio-based monomers are used to lower the crystal to liquid crystal transition temperature. Considering that the poly(oxybenzoate) can also be obtained from natural resources, the adopted route provides the unique possibility to synthesize bio-based polymers that can be used for high performance applications. To obtain the desired polymers, a synthetic route is developed to overcome the thermal instability of the 2,5-FDCA monomer. Experimental techniques, such as optical microscopy, FTIR spectroscopy, DSC, and TGA are employed to follow the polymerization, phase transitions and evaluate thermal stability of the synthesized polymers.

Thermotropic polyesters from 2,5-furandicarboxylic acid and vanillic acid: Synthesis, thermal properties, melt behavior, and mechanical performance

In this work, we address the synthesis of novel aromatic-aliphatic biobased polyesters showing thermotropic behavior in the melt. Successful incorporation of different biobased monomers such as 2,5-furandicarboxylic acid (2,5-FDCA), suberic acid (SuA), and vanillic acid (VA) in thermotropic liquid crystalline polymers (TLCPs) is made possible by performing synthesis at low temperatures. The chemical structures, molecular weights, phase transitions, thermal behavior, and mechanical performance of the synthesized polymers are studied using polarization optical microscopy, WAXD, DSC, TGA, DMTA, solid-state NMR spectroscopy, rheology, and tensile tests. It is shown that the incorporation of the rigid, aromatic 2,5-FDCA moiety enhances the formation of blocky copolymers, whereas the VA moiety tends to decrease the block formation. However, when combined, nonblocky TLCPs containing 2,5-FDCA and VA with high aromatic content can be obtained. These materials show a low temperature transition from the crystalline to the nematic phase, and stable nematic phases up to 300 °C and higher. Furthermore, in such polymers, the 2,5-FDCA and VA moieties require more thermal energy to become mobile compared to the phenyl rings in hydroxybenzoic acid, hydroquinone, and 4,4′-biphenol. Mechanical analysis shows that the performance of these polymers is correlated to their crystallinity. Surprisingly, a higher crystallinity results in ductile behavior, whereas a lower crystallinity results in a higher modulus, a higher stress at break, and a lower strain at break.

Vanillic amide derivative, and preparation method and application thereof

The invention relates to a vanillic amide derivative as shown in a formula I which is described in the specification and pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the vanillic amide derivative and the pharmaceutically acceptable salt of the vanillic amide derivative, and an application of the vanillic amide derivative, the pharmaceutically acceptable salt ofthe vanillic amide derivative and the pharmaceutical composition in preparation of an influenza virus neuraminidase inhibitor. In the formula I, R2 is Me or t-Bu; and R3 is selected from the group consisting of CO2Et, COCH3, imidazolyl, 1,2,4-triazolyl and C(= NOCH3)CH3.

COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME

The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced platelet aggregation; a pharmaceutical composition containing the same as an active ingredient; and a preparation method therefor.

A Convergent Total Synthesis of the Biologically Active Benzofurans Ailanthoidol, Egonol and Homoegonol from Biomass-Derived Eugenol

An efficient, general synthetic protocol for the synthesis of the biologically active benzofurans ailanthoidol, egonol and homoegonol was developed. The key starting material, eugenol, is a naturally occurring and abundant precursor. The protocol, involving sequential acylation and intramolecular Wittig reaction, provides a convenient method for building the benzofuran moiety in good yield.

Polymerizable compound, the photopolymerizable composition and the optical anisotropic

PURPOSE: A polymerizable naphthoic acid phenyl compound is provided to have high reflection anisotropy and high storage stability and high orientation. CONSTITUTION: A polymerizable naphthoic acid phenyl compound is represented by chemical formula 1. In chemical formula 1, one of M^1-M4 is a fluorine atom, a chlorine atom, a cyno group, a nitro group, a C1-7 alkyl group, a C1-7 alkoxy group, or a C1-7 alkanoyl group. L^1-L^6 is hydrogen, fluorine or chloride. A polymerizable liquid composition comprises the polymerizable compound. The polymer is obtained by polymerizing the polymerizable liquid compositions. An optical anisotropic object uses the polymer.

Polymerizable liquid crystal compound

PROBLEM TO BE SOLVED: To provide: a polymerizable compound which exhibits high storage stability, high cholesteric alignment and short pitch when a polymerizable liquid crystal compound is configured using the polymerizable compound; a polymerizable liquid crystal composition containing the polymerizable compound; a polymer obtained by polymerizing the polymerizable liquid crystal composition; and an optical anisotropic substance obtained by using the polymer.SOLUTION: The polymerizable compound represented by general formula (I) is provided. Further, there are provided the polymerizable liquid crystal composition containing the polymerizable compound, the polymer obtained by polymerizing the polymerizable liquid crystal composition, and the optical anisotropic substance obtained by using the polymer.

A polymerizable compound having an unsaturated ring structure

PROBLEM TO BE SOLVED: To provide a polymerizable compound which does not bring about precipitation of crystals or the like when added to a polymerizable composition, and which has high storage stability, to provide the polymerizable composition containing the polymerizable compound, from which a polymer obtainable by polymerization is produced and the polymer exhibits only slight wavelength and temperature dependence of its phase difference, and in addition to provide the polymer obtained by polymerization of the polymerizable composition and an optically anisotropic body using the polymer.SOLUTION: A compound represented by general formula (I) is provided. Moreover, a polymerizable composition including the compound as a component, a polymer obtained by polymerization of the polymerizable composition, and an optically anisotropic body using the polymer are provided.